|
Vertex Lines Up GSK, Janssen for Hep C Partnerships
Vertex plans to work separately with both GlaxoSmithKline (GSK) and Johnson & Johnson’s Janssen on studies of an all-oral therapy for treating hepatitis C using Vertex’s polymerase inhibitor VX-135.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives